Commonly used immunotherapies for HCC include anti-PD-1 (nivolumab, pembrolizumab, camrelizumab, toripalimab and sintilimab), anti-PD-L1 (atezolizumab, durvalumab and tislelizumab) and anti-CTLA-4 (ipilimumab and tremelimumab) antibodies. This evidence concerns the gene CD274 and hepatocellular carcinoma.